May 16-19, 2004, Crystal Gateway Marriott,
Arlington, VA
PROGRAM:
TUESDAY, MAY 18TH
8:00AM-9:00AM
CONTRIBUTED PODIUM PRESENTATIONS
– SESSION II
Research studies on the following topics will be discussed:
HEALTH CARE REIMBURSEMENT
HR1
DO DRUG PRICES REFLECT VALUE? DO FORMULARY
POLICIES? Neumann PJ, Lin PJ, Rosen AB, Greenberg D, Olchanski NV,
Weinstein MC
Harvard School of Public Health, Boston, MA, USA
HR2
DECISION-MAKER’S PERCEPTIONS OF ACCESS TO HIGH
COST DRUGS (HCDS) IN PUBLIC HOSPITALS IN AUSTRALIA Gallego G, Taylor S, Brien JAE
The University of Sydney, Sydney, NSW, Australia
HR3
COMPARISON OF REIMBURSEMENT SYSTEMS OF VARIOUS
COUNTRIES IN CENTRAL AND EASTERN EUROPE, AFRICA, AND MIDDLE EAST Davey P, Lees M, Makino K, Price N, Birinyi-Strachan L
M-TAG Pty Ltd, Chatswood, NSW, Australia
HR4
IMPACT OF MEMBER COST-SHARING LEVELS ON
POPULATION-BASED STATIN USE RATES Moore JM, Xiao JQ, Marks A
Caremark, Inc, Northbrook, IL, USA
HEALTH CARE COST EVALUATION
CE1 THE EFFECT OF HAVING A PRIMARY CARE PROVIDER
ON ASTHMA HEALTH CARE
EXPENDITURE AND HEALTH CARE UTILIZATION Nurmagambetov T, Atherly A, Williams S, Redd S
Centers for Disease Control and Prevention, Atlanta, GA, USA
CE2
PANEL ANALYSIS OF CENSORED MEDICAL COST DATA Baser O1, Gardiner J2, Bradley C2,
Yuce H2, Given C2 1The MEDSTAT Group, Ann Arbor, MI, USA; 2Michigan
State University, East Lansing, MI, USA
CE3
THE COSTS OF ADJUVANT CHEMOTHERAPY IN EARLY STAGE
BREAST CANCER PATIENTS: COMPARISON OF ATTRIBUTABLE COST AND MICROCOSTING
APPROACHES Oestreicher N1, Veenstra D1, Linden H2,
McCune J2, Ramsey S2 1University of Washington, Seattle, WA, USA; 2University
of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
CE4
AN ACTUARIAL APPROACH TO ESTIMATING THE STREAM OF
COSTS ASSOCIATED WITH BREAST AND COLORECTAL CANCER van der Heijde MK
Milliman USA, Denver, CO, USA
HEALTH CARE MODELING
HM1
6958 INDIVIDUALIZED PREDICTIVE DISEASE MODELING AS
A TOOL TO IMPROVE EFFICACY AND EFFICIENCY OF DISEASE MANAGEMENT PROGRAMS
FOR DIABETES MELLITUS Weber C, Woehl A, Schumacher A,
Mast O Institute for Medical Informatics and Biostatistics, Basel,
Switzerland
HM2
MODELS IDENTIFYING VARIABLES INFLUENCING PHYSICIAN
ADOPTION OF NEWLY LAUNCHED PHARMACEUTICALS IN THE UNITED STATES Mayo KW, Glass H, Lee D
University of the Sciences in Philadelphia, Philadelphia, PA, USA
HM3
PREDICTING PHARMACY COSTS USING HEALTH-RELATED
QUALITY-OF-LIFE AND PHARMACY CLAIMS MEASURES IN ADULT ASTHMATICS Meyer C, Liberman J, Cooper D, Kalmanowicz J, Chaudry S
AdvancePCS, Hunt Valley, MD, USA
HM4
HOW ROBUST IS COST-EFFECTIVENESS RATIO TO MISSING
DATA IMPUTATION? ANALYSIS OF LONG-TERM CLINICAL TRIAL IN PARKINSONS
DISEASE Noyes K, Holloway RG, Dick AW
University of Rochester School of Medicine, Rochester, NY, USA
SCREENING
SC1
PATIENT PREFERENCES FOR COLORECTAL CANCER (CRC)
SCREENING STRATEGIES Marshall DA1, Marshall JK1, Phillips KA2,
Johnson RF3, Thabane L1, Foster G1,
O'Brien B1 1McMaster University, Hamilton, ON, Canada; 2University
of California San Francisco, San Francisco, CA, USA; 3Research
Triangle Institute, NC, USA
SC2
COST EFFECTIVENESS OF SCREENING AND STATIN THERAPY
IN CLINICAL GUIDELINES FOR CARDIOVASCULAR PROPHYLAXIS Milne RJ, Gamble GD
University of Auckland, Auckland, New Zealand
SC3
FACTORS IMPACTING MAMMOGRAPHY SCREENING IN RURAL
AND URBAN AREAS Khan N
University of Illinois at Chicago, Chicago, IL, USA
SC4E
ECONOMIC EVALUATION OF SCREENING FOR THE A-ADDUCIN
GENE VARIANT IN HYPERTENSIVE PATIENTS Meckley LM, Veenstra DL
University of Washington, Seattle, WA, USA
MODERATOR: Peter Neumann ScD, Associate
Professor of Policy and Decision Sciences, Harvard School of Public Health,
Boston, MA, USA PANELISTS: Diane Simison PhD, Principal,
PharmAnalysis Group, Inc., Alexandria, VA, USA; Ronald
J. Ozminkowski PhD, Director, Health and Productivity Management
Research, Medstat, Ann Arbor, MI, USA
MODERATOR: Adrian Towse, Director, Office
of Health Economics, London, UK PANELISTS: Michael Drummond DPhil,
Director, Centre for Health Economics, York, UK;
Andreas Laupacis MD, MSc, FRCPC, President & CEO, Institute for
Clinical Evaluative Sciences, Toronto, ON, Canada;
Pete Fullerton PhD, Professor (Affiliate) University of Washington,
WA, USA
MODERATOR: Deborah Marshall, PhD, Assistant
Professor, McMaster University and Innovus Research Inc, Burlington, ON,
Canada PANELISTS: Reed Johnson, PhD, Senior
Fellow, Research Triangle Institute, Research Triangle Park, NC, USA;
Kathryn Phillips, PhD, Associate Professor,
University of California, San Francisco, CA, USA
MODERATOR: Michael B. Nichol PhD, Associate
Professor & Chair, University of Southern California, Los Angeles, CA, USA PANELISTS: Robert Kaplan PhD, Chair/Professor, University
of California, San Diego, San Diego, CA, USA;
Christopher McCabe PhD, Depute Director, NICE
Decision Support Unit, University of Sheffield, UK
Lieven Annemans PhD, MSc, Mman, 2004-2005 ISPOR President and Director, HEDM
University of Ghent, Meise, Belgium
11:30AM-12:30PM
SECOND PLENARY SESSION
NEW DIRECTIONS IN RISK SHARING AND POST MARKETING
ECONOMIC EVALUATION
Moderator:Newell McElwee PharmD, MSPH, Vice
President US Outcomes Research, Pfizer, Inc., New York, NY, USA
Speakers:Andreas Laupacis MD, MSc, FRCPC,
President & CEO and Senior Scientist, Institute for Clinical Evaluative
Sciences, Toronto, Ontario, Canada; Monique Mrazek
PhD, Health Economist, Europe and Central
Asia, The World Bank, Washington DC, USA; Adrian
Towse MA, Mphil,
Director, Office of Health Economics, London, United Kingdom
Risk Sharing Models: A Review Of International Experience
Evaluating Cost-Effectiveness And Sharing Risk: The Case Of MS Drugs
Disease Management And Risk Sharing In US
Managed Care
12:30PM-1:30PM
LUNCH, EXHIBITS,
GRAND OPENING OF CONTRIBUTED POSTER
PRESENTATIONS VIEWING – SESSION II
1:30PM-2:30PM
CONTRIBUTED
WORKSHOPS – SESSION III
Clinical study methodology issues including pharmacoepidemiology
ISPOR Medical Device
Forum: PROs in Device Evaluation: Scientific and Regulatory Challenges
Accumulation & Presentation of Scientific Evidence – Regulatory Perspective
Speaker: Neal I. Muni, MD, MSPH, Medical
Officer, FDA
The regulatory requirements & concerns; examples of successful device
“claims”, will be discussed.
4:00PM-4:05PM Introduction to the Issue - Common Challenges, Uncommon Solutions
Moderator & Speaker: Nancy Kline Leidy PhD,
President and CEO, MEDTAP International, Bethesda, MD, USA
The need to communicate value through rigorous scientific evidence common
challenge to all areas of health care, including pharma & device, will be
discussed.
4:05PM-4:15PM Overview of PRO Challenges - The Device Industry Perspective
Speaker: Randel Richner MPH, BSN, Vice
President, Federal Affairs, Reimbursement and Outcomes Planning, Boston
Scientific, Natick, MA, USA
What are the unique challenges of the device industry?
Speaker: TBD
The regulatory requirements & concerns; examples of successful device
"claims", will be discussed.
4:35PM-4:45PM Communicating Value - Payer Perspective
Speaker: TBD
4:45PM-5:00PM
Panel Discussion
VISION 2010 Forum
Speaker:
Gerry Oster PhD,
Vice President, Policy Analysis Inc., Brookline,
MA, USA; Marc Berger MD, Vice President,
Outcomes Research and Management, Merck & Co., Inc., West Point, PA, USA
The ISPOR Vision 2010 Committee was formed by the Board of Directors in
May 2002 and charged with assisting the Board in plotting the future
direction and activities of the Society. The Committee has completed its
deliberations and recently delivered its final report to the Board.
During this session, members of the Committee will discuss the
recommendations they have made to the Board concerning the future direction
and activities of ISPOR.
